The OncLive COVID-19 condition center page is a comprehensive resource for clinical news and expert insights on how the COVID-19 pandemic has impacted multiple areas of oncology care and practice. This page features news articles, interviews in written and video format, and podcasts encompassing data of patients with COVID-19 and cancer, oncology drugs being tested against the virus, vaccine information for patients with cancer, and more.
May 9th 2023
As more treatment options enter the oncology landscape, access to these life-changing medicines has become a paramount concern.
2023 IASLC North America Conference on Lung Cancer Satellite Symposia
Register Now!
PER's Breast Cancer Symposia in San Antonio
Register Now!
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
A Focus on Acute Myeloid Leukemia
View More
The Latest on Acute Lymphocytic Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Close Monitoring Recommended Despite Reduced Risk of COVID-19 Mortality in CLL
May 29th 2022Although lower fatality rates were reported during the omicron wave of the COVID-19 pandemic in patients with chronic lymphocytic leukemia, close monitoring and preemptive antiviral therapy is still recommended following a positive SARS-CoV-2 test, particularly in patients with close hospital contacts and those older than 70 years of age with at least one comorbidity.
COVID-19 Mortality Rates Rise With Hospitalization and Rituximab Treatment in MCL
May 6th 2022The overall mortality rate for patients with mantle cell lymphoma who contract COVID-19 is high, and mortality rates rise significantly in patients who are hospitalized or enter intensive care units, according to findings from a retrospective study that were published in Hemasphere.
COVID-19 Vaccine Elicits Varied Immune Responses in cGVHD
April 27th 2022Administration of the SARS-CoV-2 vaccine resulted in heterogeneous immune response in patients with chronic graft-vs-host disease (cGVHD), further highlighting concerns about protection against infection or severe COVID-19 disease in this population
Study Reveals Increased Disparities in Cervical Cancer Screening Linked With COVID-19 Pandemic
Women of all races and ethnicities who were referred to a colposcopy clinic for cervical cancer screening following an abnormal Pap smear during the COVID-19 pandemic had a higher likelihood of not adhering to their appointment compared with appointment data collected prior to the pandemic.
Third Dose of COVID-19 Vaccine Improves Response in Patients Treated with HCT and Cellular Therapies
Muhammad Bilal Abid, MD, MRCP, discusses clinical takeaways regarding the standard use of a third SARS-CoV-2 mRNA vaccine dose among patients treated with hematopoietic cell transplantation, CAR T-cell therapy, and bispecific T-cell engagers.
Prior Rituximab Reduces the Effectiveness of COVID-19 Vaccination in Lymphoma
February 9th 2022Treatment with rituximab prior to COVID-19 vaccination nearly halved the number of patients with B-cell non-Hodgkin lymphoma who developed blocking antibodies following COVID-19 vaccination compared with healthy controls.
FDA Grants Emergency Use Authorization to Long-Acting Antibody Combo for COVID-19 Prevention
The long-acting antibody combination of tixagevimab co-packaged with cilgavimab has been granted emergency use authorization in the United States for the pre-exposure prophylaxis of COVID-19.
Active Disease, ICU Deferral Linked With COVID-19–Related Mortality in AML, ALL, and MDS
Mortality rates in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were higher compared with non-cancer populations who were infected with the virus.
Oncology Drug Regulation Faces an Uncertain Future
December 1st 2021Maurie Markman, MD, discusses how agency leaders should be encouraged to improve regulatory science, include a patient’s perspective in approval decisions, reduce unnecessary bureaucracy and costs associated with the conduct of trials, and accelerate the overall review process for drug approval.
mRNA COVID-19 Vaccines May Decrease Efficacy in Lymphoid Malignancies
November 19th 2021Patients with lymphoid malignancies, especially those who have received recent anti-CD20 antibody therapy, have reduced humoral responses to the mRNA COVID-19 vaccines, and as such, should continue to take precautionary measures against COVID-19 infection irrespective of vaccination status.
Mortality Rate Associated With COVID-19 Breakthrough Cases Remains High in Hematologic Malignancies
November 18th 2021Although mortality rates in patients with hematologic cancers who develop breakthrough COVID-19 cases after vaccination are high, there has been a significant decrease in incidence since vaccines have become available.
Loss of In-Person Patient Interaction is Key Factor in Pandemic-Related Burnout Among Oncologists
November 17th 2021Although community oncologists and hematologists were concerned about loss of income during the COVID-19 pandemic, the loss of in-person patient interaction was cited as the key factor impacting their professional satisfaction.
COVID-19 Vaccination Remains Imperative for Patients with Cancer
As the COVID-19 pandemic persists, patients with cancer should receive the full vaccination with 1 of the 3 approved COVID-19 vaccines as soon as they are able, according to Steven Ludlow, PharmD, BCOP, BCPS.
CT-Based Imaging Demonstrates Utility for Early COVID-19 Identification in Lung Cancer
October 29th 2021Routine computed tomography-based imaging scans identified abnormal ground-glass opacities and infiltrates indicative of COVID-19 in patients with lung cancer undergoing radiation therapy, enabling earlier diagnosis, treatment, and risk reducing measures.
COVID-19 Vaccination Strategies Should Consider Infection Risks for CAR T-Cell Therapy Recipients
October 28th 2021Although CAR T-cell therapies have demonstrated unprecedented activity in patients with heavily pretreated relapsed/refractory hematologic malignancies, they are marked by a significant risk of infections and may limit the efficacy of COVID-19 vaccines.